PVCT (Provectus Biopharmaceuticals) 3-Year EPS without NRI Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provectus Biopharmaceuticals 3-Year EPS without NRI Growth Rate?

Provectus Biopharmaceuticals PVCT -1.26% 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. The stock has 2 warning signs investors should review. Among 1,155 Biotechnology companies, Provectus Biopharmaceuticals ranks worse than 86580% on this metric.

Provectus Biopharmaceuticals's EPS without NRI for the three months ended in Jun. 2026 was $-0.00.

During the past 5 years, the average EPS without NRI Growth Rate was 9.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 23.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Provectus Biopharmaceuticals was 44.80% per year. The lowest was -111.90% per year. And the median was 15.70% per year.

Provectus Biopharmaceuticals  (OTCPK:PVCT) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Provectus Biopharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

PVCT vs TVRD, DYAI, CLRB: 3-Year EPS without NRI Growth Rate Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provectus Biopharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.


Provectus Biopharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Provectus Biopharmaceuticals (PVCT) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Provectus Biopharmaceuticals and its competitors. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 1155 companies in the Biotechnology industry.
Is Provectus Biopharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Provectus Biopharmaceuticals' current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 1155 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Provectus Biopharmaceuticals' 3-Year EPS without NRI Growth Rate compare to TVRD and DYAI?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 1155 companies for 3-Year EPS without NRI Growth Rate. This places Provectus Biopharmaceuticals in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Provectus Biopharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provectus Biopharmaceuticals's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current 3-Year EPS without NRI Growth Rate of 0.00%. The current 3-Year EPS without NRI Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.